These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1695128)

  • 1. Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.
    Comella P; Abate G; Di Finizio G; Daponte A; Zarrilli D
    Cancer Chemother Pharmacol; 1990; 26(4):306-9. PubMed ID: 1695128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
    Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
    Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage combination chemotherapy with cisplatinum, etoposide and bleomycin in refractory non-Hodgkin's lymphomas.
    Comella P; Abate G; Di Finizio G; Fiore M; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1262-3. PubMed ID: 16312858
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
    O'Donnell MR; Forman SJ; Levine AM; Territo M; Farbstein MJ; Fahey JL; Gill P; Lazar G; Nademanee A; Neely S
    Cancer Treat Rep; 1987 Feb; 71(2):187-9. PubMed ID: 3802114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
    Vitolo U; Orsucci L; Bertini M; Cavallero G; Gallamini A; Ghio R; Levis A; Rota-Scalabrini D; Resegotti L
    Haematologica; 1991; 76(1):43-6. PubMed ID: 2055560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose etoposide and cisplatin in refractory or recurrent non-Hodgkin's lymphomas (NHL).
    Colombat P; Biron P; Patte C; Harousseau JL; Demeocq F; Benz-Lemoine E; Frappaz D; Lamagnère JP; Philip T
    Nouv Rev Fr Hematol (1978); 1990; 32(3):183-6. PubMed ID: 2216702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
    Buzzoni R; Colleoni M; Nelli P; Nolè F; Bajetta E
    Leuk Lymphoma; 1994 Jun; 14(1-2):121-8. PubMed ID: 7920218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas.
    Goss P; Shepherd F; Scott JG; Baker M; Sutton D; Sutcliffe S
    Leuk Lymphoma; 1995 Jun; 18(1-2):123-9. PubMed ID: 8580814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma.
    Helms SR; Oblon DJ; Braylan RC; Weiner RS
    Cancer Treat Rep; 1985; 69(7-8):783-6. PubMed ID: 2410118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphomas of the unfavorable histologic subtypes.
    Winter JN; Gordon LI; Hauck WW; Variakojis D
    Cancer Treat Rep; 1986 Oct; 70(10):1243-4. PubMed ID: 3756945
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
    Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
    Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.